摘要
目的:观察康莱特联合化疗治疗晚期非小细胞肺癌的临床疗效。方法:将70例患者随机分成治疗组、对照组,各35例;2组均采用GP(吉西他滨+顺铂)化疗方案,治疗组在此基础上加用康莱特,观察2组临床疗效、生存质量、不良反应等情况。结果:治疗组近期疗效有效率为54.29%,对照组为37.14%,2组比较有显著性差异(P<0.05);治疗组KPS评分有效率为65.71%,对照组为42.86%,2组比较有显著性差异(P<0.05);2组主要不良反应为骨髓抑制及胃肠道反应,但治疗组的反应程度较对照组轻,2组比较有显著性差异(P<0.05)。结论:康莱特联合化疗治疗晚期非小细胞肺癌可提高临床疗效,减轻化疗的不良反应,提高患者生存质量。
OBJECTIVE：To study the effect of Kanglaite combined with chemical therapy on advanced non-small cell lung cancer.METHODS：70 patients were randomly divided into treatment group and control group（n=35）.Both groups were given GP regime of chemical therapy.Treatment group were additionally treated with Kanglaite.Clinical efficacy,quality of life and adverse reactions of 2 groups were observed.RESULTS：Recent response rate were 54.29% for treatment group and 37.14% for control group,there were statistical significance in difference between 2 groups（P0.05）.Response rate of KPS were 65.71% for treatment group and 42.86% for control group,there were statistical significance in difference between 2 groups（P0.05）.The common adverse reactions of 2 groups were myelosuppression and gastrointestinal reaction,but the severity of the reactions in treatment group were more slight than in control group,there were statistical significance in difference between 2 groups（P0.05）.CONCLUSION：Kanglaite combined with chemotherapy can improve clinical efficacy of therapy for advanced non-small cell lung cancer,reduce the toxic adverse reaction and improve the quality of life.
出处
《中国药房》
CAS
CSCD
北大核心
2010年第20期1860-1861,共2页
China Pharmacy
关键词
非小细胞肺癌
康莱特
生存质量
Non-small cell lung cancer
Kanglaite
Quality of life
